Generic Drugs: What does equal really mean? Dr. Peter J. Lin Director Primary Care Initiatives Canadian Heart Research Centre

Size: px
Start display at page:

Download "Generic Drugs: What does equal really mean? Dr. Peter J. Lin Director Primary Care Initiatives Canadian Heart Research Centre"

Transcription

1 Generic Drugs: What does equal really mean? Dr. Peter J. Lin Director Primary Care Initiatives Canadian Heart Research Centre

2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.

3 $20 million to test quality of Generics

4 Antihypertensive Agents Currently Available in Canada ACE-Is Benazepril Captopril ARBs Candesartan Irbesartan Beta-blockers Acebutolol Atenolol CCBs Amlodipine Diltiazem Diuretics Acetazolamide Furosemide Renin inhibitors Aliskiren Cilazapril Losartan, Bisoprolol Felodipine Hydrochlorothiazide Enalapril Olmesartan Labetolol Nifedipine Indapamide Fosinopril Telmisartan Metoprolol Verapamil Metolazone Lisinopril Valsartan Nadolol Spironolactone Perindopril Pindolol Triamterene Quinapril Propanolol Ramipril Timolol Trandolapril ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CCB = calcium channel blocker

5 Antihypertensive Agents Currently Available in Canada ACE-Is Benazepril Captopril ARBs Candesartan Irbesartan Beta-blockers Acebutolol Atenolol CCBs Amlodipine Diltiazem Diuretics Acetazolamide Furosemide Renin inhibitors Aliskiren Cilazapril Losartan, Bisoprolol Felodipine Hydrochlorothiazide Enalapril Olmesartan Labetolol Nifedipine Indapamide Fosinopril Telmisartan Metoprolol Verapamil Metolazone Lisinopril Valsartan Nadolol Spironolactone Perindopril Pindolol Triamterene Quinapril Propanolol Ramipril Timolol Trandolapril ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CCB = calcium channel blocker

6 FDA Companies had to prove that a drug was both safe and effective before it reached the market place. All new drugs had to go through a lengthy and expensive process that included large-scale human trials Impala

7 Scientific Investigations Preclinical Phase 1 Phase 2 Phase 3 Phase 4 REVIEWERS NDA Chemist Microbiologist Pharmacologist Biopharmaceutist Clinician Statistician Advisory Committee Compliance (CMC) Drug Advertising Office Drug Safety 7

8

9 Production Sameness Discovery Safety Efficacy

10 The FDA Process for Approving Generic Drugs Gary J. Buehler, R.Ph. Dale Conner, Pharm. D. Director Director, Division of Bioequivalence Office of Generic Drugs

11 Hatch-Waxman Amendments to FFD&C Act Allowed generic firms to rely on findings of safety and efficacy of innovator drug after expiration of patents and exclusivities (do not have to repeat expensive clinical and pre-clinical trials) Center for Drug Evaluation & Research U.S. Food & Drug Administration 11

12 Human bioequivalence studies have been required for generic drugs since 1984 Bioequivalence refers to the absence of a significant difference in the rate at which or the extent to which the active ingredient in pharmaceutical equivalents becomes available at the site of drug action when two drug products are administered under similar experimental conditions in an appropriately designed study. Welage LS et al. J Am Pharm Assn 2001;41(6): Abstract

13 Human bioequivalence studies have been required for generic drugs since 1984 Bioequivalence refers to the absence of a significant difference in the rate at which or the extent to which the active ingredient in pharmaceutical equivalents becomes available at the site of drug action when two drug products are administered under similar experimental conditions in an appropriately designed study. Non-Inferiority Study Welage LS et al. J Am Pharm Assn 2001;41(6): Abstract

14 What are the requirements for a generic drug? Same active ingredient(s) Same route of administration Same dosage form Same strength Same conditions of use Compared to reference listed drug (RLD) - (brand name product) Center for Drug Evaluation & Research U.S. Food & Drug Administration 14

15 In proving that their products are safe and effective, generic drug manufacturers have two options. 1. One is to repeat most of the chemistry, animal and human studies done by the manufacturer of the original brand name drug. 2. The other is to show how the generic drug performs compared with the original brand name drug. In comparative bioavailability studies, the level of a medicinal ingredient in the blood of healthy human volunteers is measured. During the studies each volunteer receives the original brand name drug and the new generic drug on two separate occasions. The generic drug must show that it can deliver the same amount of medicinal ingredient at the same rate as the original brand name drug. 15

16 Bioequivalence Example Test/Generic Reference/Brand

17 Bioequivalence Example Test/Generic Reference/Brand AUC

18 Bioequivalence Health Canada The relative mean measured AUC of the modified-release formulation to the conventional formulation should be between 80% and 125% in the fasting state. Source: Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part B: Oral Modified Release Formulations.

19 In proving that their products are safe and effective, generic drug manufacturers have two options. 1. One is to repeat most of the chemistry, animal and human studies done by the manufacturer of the original brand name drug. 2. The other is to show how the generic drug performs compared with the original brand name drug. In comparative bioavailability studies, the level of a medicinal ingredient in the blood of healthy human volunteers is measured. During the studies each volunteer receives the original brand name drug and the new generic drug on two separate occasions. The generic drug must show that it can deliver the same amount of medicinal ingredient at the same rate as the original brand name drug. 19

20 What does Equal Mean? -20% +25% 80% 125% 45% Window

21 What does Equal Mean? -20% +25% 80% 125% 45% Window

22 How many people do you need to test? 12

23 FACT: Research shows that generics work just as well as brand name drugs. A recent study evaluated the results of 38 published clinical trials that compared cardiovascular generic drugs to their brand-name counterparts. There was no evidence that brand-name heart drugs worked any better than generic heart drugs. [Kesselheim et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21) ]. Generic only 3% off

24 Looked at 8556 studies only 47 matched criteria

25

26 Generic and Brand-Name Drugs Used in Cardiovascular Disease 30 Studies 837 Patients 28 per study

27 Labeling Same as brand name labeling May delete portions of labeling protected by patent or exclusivity May differ in excipients, PK data and how supplied Center for Drug Evaluation & Research U.S. Food & Drug Administration 27

28 Inactive Ingredients Prinivil (Lisinopril) Merck & Co Inactive Ingredients in 20mg dose 1.Calcium Phosphate 4. Starch 2.Mannitol 5. Iron Oxide 3.Magnesium Sterate Lisinoril by Mylan Inc. Generic Inactive ingredients in 20 mg dose 1.Collidal Sillicon Oxide 5. Providone 2.Croscarmellose sodium 6. pregelatinized starch 3.Diabasic calcium phosphate 7.Sodium lauryl sulfate 4.Mannitol 8.D&C Yellow #10 Aluminum lake HT Generic version almost doubles the inactive ingredients Additional ingredients may increase the risk for allergic response and pharmacists rarely caution patients against potential adversities and no labeling is required. It is unclear how these ingredients will effect the outcomes of the drug. Ex. sodium lauryl sulfate is (surfactant soap) that can be used in a degreaser

29 Inactive Ingredients Prinivil (Lisinopril) Merck & Co Inactive Ingredients in 20mg dose 1.Calcium Phosphate 4. Starch 2.Mannitol 5. Iron Oxide 3.Magnesium Sterate Lisinoril by Mylan Inc. Generic Inactive ingredients in 20 mg dose 1.Collidal Sillicon Oxide 5. Providone 2.Croscarmellose sodium 6. pregelatinized starch 3.Diabasic calcium phosphate 7.Sodium lauryl sulfate 4.Mannitol 8.D&C Yellow #10 Aluminum lake HT Generic version almost doubles the inactive ingredients Additional ingredients may increase the risk for allergic response and pharmacists rarely caution patients against potential adversities and no labeling is required. It is unclear how these ingredients will effect the outcomes of the drug. Ex. sodium lauryl sulfate is (surfactant soap) that can be used in a degreaser

30 Heat Humidity

31 Ramipril vs 22 Generics

32 Ramipril vs 22 Generics

33

34 STABILITY: Metabolite Ramipril-diketopiperazine (DKP)

35

36 UK Switch to Simvastatin Phillips, Br J Cardiol 2007;14:280-5

37 Epilepsy switch to Levetiracetam November 1, 2008 all patients switched to generic Retrospective Chart review 260 patients 105 patients Switched back (42.9%) % Patients with Increased in seizure frequency: 19.6% vs 1.6% p< Polytherapy: ( ) p<0.05 Epilepsia Apr;52(4): doi: /j x. Epub 2011 Mar 22.

38

39 N=37,756 Brand only = Generic=20, 292 Switchers = 12,996 Hemorrhagic Events Ann Pharmacother 2011;45:701-12

40 N=37,756 Brand only = Generic=20, 292 Switchers = 12,996 Thrombotic Events Ann Pharmacother 2011;45:701-12

41 Clinical/PD Response Clinical/PD Dose-Response Log Dose Center for Drug Evaluation & Research U.S. Food & Drug Administration 41

42 FDA has approved five generic versions of Wellbutrin XL 300 mg. Each of these generics was approved based on bioequivalence studies comparing the 150 mg strength of the products to Wellbutrin XL 150 mg. Studies were not performed directly on the 300 mg strength of the products. Rather, the bioequivalence studies were performed using the 150 mg strength, and the results were extrapolated to establish bioequivalence of the 300 mg product. This methodology was based on FDA s guidance at the time the products were approved. FDA has determined that this approach is no longer appropriate to establish bioequivalence of 300 mg bupropion hydrochloride extended-release tablets to Wellbutrin XL 300 mg, and the Agency is revising its guidance to industry for how to conduct premarket bioequivalence studies in generic bupropion products.

43 Ranbaxy Because this company continued to violate current good manufacturing practice regulations and falsify information on drug applications, the FDA took these actions in an effort to protect consumers, said Dara Corrigan, FDA associate commissioner for regulatory affairs.

44 May 15, Substitute Cheaper, Lower Quality 2. Substitute brand name drugs in lieu of their own generics in bioequivalance tests to produce better results

45

46

47

48 48

49

50

51 $20 million to test quality of Generics

52 Thanks for Staying Awake

ASEBP and ARTA TARP Drugs and Reference Price by Categories

ASEBP and ARTA TARP Drugs and Reference Price by Categories ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole

More information

Factors Involved in Poor Control of Risk Factors

Factors Involved in Poor Control of Risk Factors Factors Involved in Poor Control of Risk Factors Patient compliance Clinical inertia Health Care System structure 14781 M Limitations of Formal Studies Selection of patients Recruitment and follow-up alter

More information

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:

More information

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical

More information

Conversion of losartan to lisinopril

Conversion of losartan to lisinopril Cari untuk: Cari Cari Conversion of losartan to lisinopril Dania Alsammarae, Strategy Director and co-founder of Anglo Arabian Healthcare speaks with Neil Halligan of Arabian Business on what it takes

More information

Select Preventive Prescription Drugs Jan. 1, 2018

Select Preventive Prescription Drugs Jan. 1, 2018 Select Preventive Prescription Drugs Jan. 1, 2018 In addition to a healthy lifestyle, preventive medications can help you avoid some illnesses and conditions. Zimmer Biomet's medical options Value HSA,

More information

ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR

ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR S/N ME OF MEDICATIONS BRANDED/GENERIC DRUG CLASS * UNIT PRICE RANGE (SGD$) 1 ACEBUTOLOL HCL 100MG CAPSULE SECTRAL BETA BLOCKERS 0.50 2 ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS 0.33 3 ALISKIREN

More information

12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)

12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER) MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB

More information

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1

More information

Chapter 2 ~ Cardiovascular system

Chapter 2 ~ Cardiovascular system Chapter 2 ~ Cardiovascular System: General Section 1 of 6 Chapter 2 ~ Cardiovascular system 2.1 Positive inotropic drugs 2.1.1 Cardiac glycosides DIGOXIN 2.2 Diuretics Elixir 50micrograms in 1ml Injection

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Guide to the Modernized Reference Drug Program

Guide to the Modernized Reference Drug Program Guide to the Modernized Reference Drug Program For prescribers and pharmacists Medical Beneficiary and Pharmaceutical Services Division June 1, 2016 Contents 1 Introduction 1 2 About this Guide 2 3 About

More information

Lisinopril 20 converting to losartan

Lisinopril 20 converting to losartan Search Lisinopril 20 converting to losartan Stop wasting your time with unanswered searches. lisinopril 40 mg to losartan conversion,cannot Find low price Best. Winds SSW at 10 to 20. Lisinopril 20 to

More information

Antihypertensive Agents

Antihypertensive Agents Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,

More information

The ADDITION Study: A study about screening for diabetes. Screening Case Report Form

The ADDITION Study: A study about screening for diabetes. Screening Case Report Form ADDITION Study, Leicester Participant Identification Label: Date: / / The ADDITION Study: A study about screening for diabetes Screening Case Report Form You will need to have the following things done

More information

DRUG CLASSIFICATION. Prevention of Cardiovascular Disease

DRUG CLASSIFICATION. Prevention of Cardiovascular Disease Generic Preventive Care/ Safe Harbor Drug Program List Preventive care/safe harbor drugs are drugs that can help keep you from developing a health condition or related complications of a health condition.

More information

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Lisinopril losartan conversion dose

Lisinopril losartan conversion dose P ford residence southampton, ny Lisinopril losartan conversion dose Deep in-house technology, streaming expertise, and partnerships with the widest range of digital platforms secures our position as the

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated

More information

Cardiac Medications At A Glance

Cardiac Medications At A Glance Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)

More information

12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg

12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 9/11/2018 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 5/17, 9/15, 2/13, 2/08, LOB

More information

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation

Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:

More information

Clinical Policy: ACEI and ARB Duplicate Therapy Reference Number: CP.PMN.61 Effective Date: Last Review Date: 05.18

Clinical Policy: ACEI and ARB Duplicate Therapy Reference Number: CP.PMN.61 Effective Date: Last Review Date: 05.18 Clinical Policy: Reference Number: CP.PMN.61 Effective Date: 08.01.14 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Annual Review of Antihypertensives - Fiscal Year 2009

Annual Review of Antihypertensives - Fiscal Year 2009 Annual Review of Antihypertensives - Fiscal Year 2009 Oklahoma HealthCare Authority April 2010 Current Prior Authorization Criteria There are 7 categories of antihypertensive medications currently included

More information

Hypertension Management - Summary

Hypertension Management - Summary Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)

More information

Chapter / Section / Drug

Chapter / Section / Drug 2 Cardiovascular System 2.1 Positive inotropic drugs Digoxin Digoxin specific antibody ( DigiFab ) 2.2 Diuretics 2.2.1 Thiazides and related diuretics Indapamide (1 st Line) Bendroflumethiazide Metolazone

More information

Losartan lisinopril equivalent dose

Losartan lisinopril equivalent dose 新着 news 2018 年 2 月 28 日 jica 国際協力中学生 高校生エッセイコンテスト 2017 表彰式 2018 年 2 月 19 日 2017 年度第 8 回卒業式を挙行. CHFpatients.com - Ace inhibitors explained in plain English - the primary drug treatment for heart failure

More information

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys

More information

Generic Preventive Care/ Safe Harbor Drug Program List

Generic Preventive Care/ Safe Harbor Drug Program List Preventive care/safe harbor drugs are drugs that can help keep you from developing a health condition or related complications of a health condition. The Generic Preventive Care/Safe Harbor Drug Program

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

What in the World is Functional Medicine?

What in the World is Functional Medicine? What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

Don t let the pressure get to you:

Don t let the pressure get to you: Balanced information for better care Don t let the pressure get to you: An update on the changing recommendations for treating hypertension New trial data and guidelines have made hypertension care more

More information

Brookings Roundtable on Active Medical Product Surveillance:

Brookings Roundtable on Active Medical Product Surveillance: 2012, The Brookings Institution Brookings Roundtable on Active Medical Product Surveillance: Findings from a Mini-Sentinel Medical Product Assessment Marsha Reichman, U.S. Food and Drug Administration

More information

Cilazapril to lisinopril dose conversion

Cilazapril to lisinopril dose conversion Cilazapril to lisinopril dose conversion The Borg System is 100 % Cilazapril to lisinopril dose conversion COMPARISON OF ANGIOTENSIN CONVERTING ENZYME (ACE). INHIBITORS. Drug. Approximate. Dose. Equivalence.

More information

Physician/Clinic Collaborative Practice Agreement

Physician/Clinic Collaborative Practice Agreement Physician/Clinic Collaborative Practice Agreement Effective October 1, 2010, Connecticut Senate Bill 428 (PA 10-117) extends to all settings and medical conditions the opportunity for licensed pharmacists

More information

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided

More information

Lisinopril to losartan equivalent

Lisinopril to losartan equivalent Your browser does not support script 22-11-2011 Specifically, Lisinopril (brand names include Prinivil and Zestril) is the third most-prescribed drug in the US, according to WebMD Health News (April 20.

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC

DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC DROGAS PARA HIPERTENSION ARTERIAL JONATHAN POVEDA FERNANDEZ HSJD / 2013 FACC/FSCAI/FESC Pharmacotherapy of HTN Rationale for reducing arterial pressure Reduce cardiac output Reduce heart rate Reduce stroke

More information

ISMJ International SportMed Journal

ISMJ International SportMed Journal 32 ISMJ International SportMed Journal FIMS Position Statement Antihypertensive medications and exercise Associate Professor Wayne Derman UCT/MRC Research Unit for Exercise Science and Sports Medicine,

More information

Study Exposures, Outcomes:

Study Exposures, Outcomes: GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic

More information

C o n t i n u i n g E d u c a t i o n

C o n t i n u i n g E d u c a t i o n C o n t i n u i n g E d u c a t i o n tech talkce the national continuing education program for pharmacy technicians 1 CEU Answer online for instant results www.pharmacygateway.ca February/March 2008 Approved

More information

Clinical Policy: Angiotesin II Receptor Blockers and Renin Inhibitors Reference Number: CP.HNMC.15 Effective Date: Last Review Date: 08.

Clinical Policy: Angiotesin II Receptor Blockers and Renin Inhibitors Reference Number: CP.HNMC.15 Effective Date: Last Review Date: 08. Clinical Policy: Reference Number: CP.HNMC.15 Effective Date: 11.16.16 Last Review Date: 08.17 Revision Log Line of Business: Medicaid Medi-Cal See Important Reminder at the end of this policy for important

More information

Losartan lisinopril equivalent dose 新着 news 2018 年 3 月 6 日高等部 3 年生 大阪リゾート & スポーツ専門学校に合格! 2018 年 3 月 2 日茨木市立山手台小学校との交流.

Losartan lisinopril equivalent dose 新着 news 2018 年 3 月 6 日高等部 3 年生 大阪リゾート & スポーツ専門学校に合格! 2018 年 3 月 2 日茨木市立山手台小学校との交流. P ford residence southampton, ny Losartan lisinopril equivalent dose 新着 news 2018 年 3 月 6 日高等部 3 年生 大阪リゾート & スポーツ専門学校に合格! 2018 年 3 月 2 日茨木市立山手台小学校との交流. Losartan is classified as FDA pregnancy risk category

More information

Antihypertensive Drug Procurement Trends from 1995 to 2004: Transition over a Decade. Khalid AJ Al Khaja, PhD*

Antihypertensive Drug Procurement Trends from 1995 to 2004: Transition over a Decade. Khalid AJ Al Khaja, PhD* 1 Bahrain Medical Bulletin, Vol. 34, No. 2, June 2012 Antihypertensive Drug Procurement Trends from 1995 to 2004: Transition over a Decade Khalid AJ Al Khaja, PhD* Objective: To evaluate antihypertensive

More information

Medicines for high blood pressure

Medicines for high blood pressure Patient Information: Medicines Medicines for high blood pressure Health & care information you can trust The Information Standard Certified Member Working together for better patient information What is

More information

Information in these slides is used with permission from St. Mary s Cardiac Rehab

Information in these slides is used with permission from St. Mary s Cardiac Rehab Information in these slides is used with permission from St. Mary s Cardiac Rehab Prescription Pointers Heart Medications Questions!! 2-4% of patients who visit ER s have experienced a medication misadventure

More information

Amlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications.

Amlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications. Page 1 of 8 Policies Repository Policy Title Policy Number Oral Antihypertensive Agents FS.CLIN.9 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product

More information

Ambetter 90-Day-Supply Maintenance Drug List

Ambetter 90-Day-Supply Maintenance Drug List Ambetter 90-Day-Supply Maintenance Drug List What is the Ambetter 90-Day-Supply Maintenance Drug List? Ambetter 90-Day-Supply Maintenance Drug List is a list of maintenance medications that are available

More information

Drug Regimen Optimization

Drug Regimen Optimization Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description

More information

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy

More information

Don t let the pressure get to you:

Don t let the pressure get to you: Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular

More information

Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013

Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013 Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013 QUALITY PERFORMANCE METRIC CALCULATION QUALITY METRICS SELECTED FOR MEASUREMENT Per Section 3.2 of the Agreement, HCPP must meet the following

More information

NOTES: Anemia Medical condition in which the number of red blood cells (the blood count) is reduced.

NOTES: Anemia Medical condition in which the number of red blood cells (the blood count) is reduced. Advance care planning A process in which you decide what you would like to happen to you, or not happen to you, if you become unable to make decisions about your healthcare treatment or if you are unable

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Living with Congestive Heart Failure: A Guide to a Healthy Heart

Living with Congestive Heart Failure: A Guide to a Healthy Heart Living with Congestive Heart Failure: A Guide to a Healthy Heart Things to Know, Before You Go Dear Patient/Caregiver These are the things you NEED TO KNOW, BEFORE YOU GO. It is very important that you

More information

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important? Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents

More information

Clinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.

Clinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D. Clinical Endpoint Bioequivalence Study Review in ANDA Submissions Ying Fan, Ph.D. 1 Disclaimer This presentation constitutes an informal communication that represents the best judgment of the speaker at

More information

4/3/2014 OBJECTIVES BLOOD PRESSURE BASICS. Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7

4/3/2014 OBJECTIVES BLOOD PRESSURE BASICS. Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7 1 OBJECTIVES Discuss the new blood pressure guidelines (JNC 8) and recognize the changes from JNC 7 Review mechanisms for the main drug classes used to treat hypertension Describe the dosing strategies

More information

Medications for Type 2 Diabetes CDE Exam Preparation. Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy

Medications for Type 2 Diabetes CDE Exam Preparation. Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Competency for CDE Exam 3.1.A Oral Medications for Type 2 Diabetes

More information

Trandolapril to lisinopril

Trandolapril to lisinopril Trandolapril to lisinopril Lisinopril : learn about side effects, dosage, special precautions, and more on MedlinePlus. Tansiyon, hipertansiyon ilaçlarını; antihipertansif ilaçları içerir.. Tansiyon -

More information

Beta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol.

Beta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol. Drugs of CVS Beta-blockers Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol. Atenolol.cardioselective Propranolol, nonselective Bisoprolol, cardioselective Metoprolol Carvedilol, alpha

More information

Value-Based Drug List for ABCs of Diabetes

Value-Based Drug List for ABCs of Diabetes Effective January 1, 2019 Value-Based Drug List for ABCs of Diabetes PCPS provides a Value-Based Benefit Design (VBD) to qualified participants in the ABCs of Diabetes. This means you will have lower out-of-pocket

More information

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

APPENDIX D: PHARMACOTYHERAPY EVIDENCE Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Olmesartan/Amlodipine (Azor), Olmesartan/Amlodipine/ HCTZ (Tribenzor) Reference Number: CP.CPA.XX Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial See Important

More information

QTY LIMIT COPAY (30 DAY/90 DAY) BENIGN PROSTATIC HYPERPLASIA FINASTERIDE $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8

QTY LIMIT COPAY (30 DAY/90 DAY) BENIGN PROSTATIC HYPERPLASIA FINASTERIDE $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 $4/$8 2019 LiveWELL Health Plan PREVENTIVE DRUG LIST - GENERIC Names ( Copay) - ALPHABETICAL by DRUG CATEGORY You should always check with your prescriber and/or pharmacist to determine if these alternatives

More information

8/19/2016. No Conflicts. I struggled with everything cardiac in nursing school.

8/19/2016. No Conflicts. I struggled with everything cardiac in nursing school. Cindy Weston, DNP, RN, CCRN, CNS CC, FNP BC Assistant Professor, Texas A&M Health Science Center College of Nursing Describe and define epidemiology and pathophysiology of hypertension Differentiate JNC8

More information

BIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE. Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016

BIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE. Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016 BIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE Soula Kyriacos, B.Pharm, PhD Head R&D, Pharmaline November 2016 Introduction Early 1970 s FDA regulations for submission of BA data 1984 US Congress passed the

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

ORANGE BOOK ORANGE BOOK

ORANGE BOOK ORANGE BOOK 1 INTRODUCTION: DEFINITION: The official title of the book is Approved Drug Products with Therapeutic Equivalence Evaluations. Orange book is a publication by the Food and Drug Administration which contains

More information

ACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease

ACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease ACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease Is This Guide Right for Me? This Guide Is for You If: You have coronary heart disease,

More information

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent

More information

ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut

ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut ANTIHYPERTENSIVES Assoc. Prof. Bilgen Başgut Hypertension Hypertension is a condition in which the blood pressure is persistently higher than normal Hypertension > 140 mmhg > 90 mmhg Systolic Blood Pressure

More information

Codes for a Medicare claims-based model to predict LVEF class- User Guide

Codes for a Medicare claims-based model to predict LVEF class- User Guide Description and citation: This guide accompanies our manuscript [Desai RJ, Lin KJ, Patorno E, et al. Development and Preliminary Validation of a Medicare Claims Based Model to Predict Left Ventricular

More information

Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure.

Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure. Hypertension Hypertension Hypertension is defined as either a sustained systolic blood pressure of greater than 140 mm Hg or a sustained diastolic blood pressure of greater than 90 mm Hg. Hypertension

More information

New classification of HT Systolic Diastolic Normal <120 <80 Prehypertension Stage1HT Stage 2 HT >160 or >100

New classification of HT Systolic Diastolic Normal <120 <80 Prehypertension Stage1HT Stage 2 HT >160 or >100 Hypertension 1 Definition Hypertension can be defined as a condition where blood pressure is elevated to an extent that clinical benefit is obtained from blood pressure lowering. it is an important risk

More information

Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic

Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic June Chen 1, Charlotte Galenza 1, Justin Ezekowitz 2,3,

More information

Hypertension in Primary Care: Blood Pressure Goals for Adults Aged 60 and Older

Hypertension in Primary Care: Blood Pressure Goals for Adults Aged 60 and Older Hypertension in Primary Care: Blood Pressure Goals for Adults Aged 60 and Older B.C. Provincial Academic Detailing Service November 2017 REFERENCES Background (p1) 1. Alhaawassi T, Krass I, Pont L. Hypertension

More information

Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices

Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices Chapter 2 - Cardiovascular System Primary Care Prescribing Formulary - Preferred Drug Choices Drug group Drug choice Comments/notes Cardiac glycosides Thiazide diuretics Loop diuretics Aldosterone antagonist

More information

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Antihypertensive drugs SUMMARY Made by: Lama Shatat Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone

More information

Have you been paying for your prescription drugs? Stop!

Have you been paying for your prescription drugs? Stop! Dear Valued Medtipster Member: Have you been paying for your prescription drugs? Stop! Free prescription drugs are NOW just a Medtipster ID card away. Follow the steps below to obtain thousands of generic

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 3 mg/ml oral solution B/1 160 ml (CIP code: 491 474-8) Applicant: NOVARTIS PHARMA SAS valsartan

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Diovan, Diovan HCT, Exforge, Exforge HCT, Teveten) Reference Number: CP.HNMC.16 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important

More information

Module 7: Pharmacological Management of Cardiovascular Diseases

Module 7: Pharmacological Management of Cardiovascular Diseases Module 7: Pharmacological Management of Cardiovascular Diseases Module Aim This module is an introduction to the pharmacological management of cardiovascular diseases and related risk factors. In this

More information

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured. Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.

More information

HYPERTENSION 4.0 Contact Hours Presented by: CEU Professor

HYPERTENSION 4.0 Contact Hours Presented by: CEU Professor HYPERTENSION 4.0 Contact Hours Presented by: CEU Professor 7 www.ceuprofessoronline.com Copyright 8 2007 The Magellan Group, LLC All Rights Reserved. Reproduction and distribution of these materials is

More information

Clinical Teach-Back Cards

Clinical Teach-Back Cards Clinical Teach-Back Cards The Medicare Quality Improvement Organization for Texas TMF Health Quality Institute focuses on improving lives by improving the quality of health care through contracts with

More information

Cardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist

Cardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist Cardiovascular Risk Reduction in Diabetic Mellitus Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist Cardiovascular Risk Reduction in Diabetic Mellitus Disclosures

More information

LESSON ASSIGNMENT. After completing this lesson you will be able to:

LESSON ASSIGNMENT. After completing this lesson you will be able to: LESSON ASSIGNMENT SUBCOURSE MD0806 LESSON 7 Therapeutics III. Antihypertensive Agents. LESSON ASSIGNMENT Paragraphs 7-1--7-12. LESSON OBJECTIVES After completing this lesson you will be able to: 7-1. From

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

Drug Regimen Optimization

Drug Regimen Optimization Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Understanding the Value of Generic Drugs

Understanding the Value of Generic Drugs Understanding the Value of Generic Drugs Generic drugs can help you get the most out of your health care budget. 05.02.306.1 (8/05) Many people believe that when something costs more, it must be of higher

More information

Guideline-Directed Medical Therapy

Guideline-Directed Medical Therapy Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in

More information

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park. Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed

More information

Clinical Policy: Ranolazine (Ranexa) Reference Number: CP.PMN.34 Effective Date: Last Review Date: 02.19

Clinical Policy: Ranolazine (Ranexa) Reference Number: CP.PMN.34 Effective Date: Last Review Date: 02.19 Clinical Policy: (Ranexa) Reference Number: CP.PMN.34 Effective Date: 08.01.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information